AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 12, 2026 Mirum grants inducement awards to 17 new employees, including options for 26,126 shares and 34,386 RSUs. AI-generated summary · Source: company release
NASDAQ: $MIRMBiotech · Rare diseasesClinical, capital and regulatory risk

MIRM Stock Hub: Mirum Pharmaceuticals News, Brelovitug and Volixibat

Positive AZURE-4 data are already in. Q3 net product sales reached $185.721M, with $500.455M cash and investments at September 30. Mirum now approaches VANTAGE and a broad application cycle, while acquisitions and convertibles complicate growth per share. AZURE-4 results · November 10 Q3 2026 Form 10-Q · November 3 Q3 results and current guidance · November 3

Last updated: November 12, 2026Financial period: September 30, 2026Currency: USD
Research Library · Biotech
Mirum Pharmaceuticals: Commercial Growth and the 2027 Application Cycle
LIVMARLI, ATEBRIOZ, brelovitug and volixibat · Research as of November 12, 2026
Get the report (PDF)
Next catalyst · company-guided window
Q1 2027 · VANTAGE PBC topline

Volixibat Phase 2b data are expected in the first quarter. PSC NDA, brelovitug BLA and two label-expansion filings are planned H1 2027. These are submission forecasts, not established FDA acceptance or decision dates. Q3 results and current guidance · November 3

Already completed: AZURE-4 positive November 10; AASLD presentations November 8. AZURE-4 results · November 10 AASLD portfolio data · November 8
MIRM daily price chart
Daily chart · Finviz (affiliate link on click). Explore MIRM on JC Just Charts.

MIRM stock data: financial position and capital

Chart analysis · JC
Technical chart analysis of $MIRM with bull and bear scenarios on JC Just Charts.
Q3 net product sales
$185.721M
Quarter ended September 30
Cash + investments
$500.455M
September 30; restricted cash excluded
Convertible principal
$749.035M
September 30; carrying amount $731.250M
Common shares
65.282M
October 30 cover count
2026 sales guidance
$715–720M
Raised November 3; company forecast
Health Score
3.60 / 5
Weighted editorial assessment

Financial figures from Q3 10-Q and November 3 results. Market value uses the dated close and October 30 common shares; it is not fully diluted value. Q3 2026 Form 10-Q · November 3 Q3 results and current guidance · November 3

Mirum stock: commercial progress and a larger capital claim

The $898.148M nine-month net loss includes acquired IPR&D. Operating cash use of $277.326M is acquisition-affected and is not a recurring burn estimate. Q3 2026 Form 10-Q · November 3

▲ The constructive case

LIVMARLI and Bile Acid Medicines provide a growing revenue base. ATEBRIOZ is approved in the U.S. from age 12, and positive AZURE-4 strengthens the planned brelovitug filing package. Q3 2026 Form 10-Q · November 3 ATEBRIOZ FDA approval · September 25 AZURE-4 results · November 10

▼ The cautious case

Applications and launches remain conditional; debt, equity awards, acquisition issuance and development spending complicate growth per share. Q3 2026 Form 10-Q · November 3

Latest MIRM news

Nov 12, 2026

Mirum Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4)

On November 10, 2026, Mirum's Compensation Committee granted inducement awards to 17 new employees under its 2020 Inducement Plan. The awards consist of non-qualified stock options to purchase 26,126 shares of common stock and 34,386 restricted stock units (RSUs). Each option has an exercise price of $94.42 per share, equal to the closing price on November 10, 2026. Options vest over four years and RSUs vest over three years.

Nov 10, 2026

Mirum's brelovitug meets primary endpoint in Phase 3 AZURE-4 study

Mirum Pharmaceuticals announced that brelovitug met the primary endpoint at Week 24 in the Phase 3 AZURE-4 study for chronic hepatitis delta virus. In the study of 113 treatment-naïve patients, 59% receiving 300 mg QW and 44% receiving 900 mg Q4W achieved the combined endpoint of virologic response and ALT normalization, versus 0% in the delayed-treatment arm (p≤0.0001 for both comparisons). The company plans to submit a Biologics License Application in the first half of 2027, with a potential U.S. commercial launch in the fourth quarter of 2027, if approved.

MIRM stock catalysts: VANTAGE and 2027 filings

No planned application is presented as already accepted by FDA. AZURE-4 and November AASLD data are completed events. AZURE-4 results · November 10 AASLD portfolio data · November 8

What Mirum Pharmaceuticals does

LIVMARLI inhibits IBAT and treats cholestatic pruritus within its U.S. ALGS and PFIC labels. CHOLBAM is cholic acid; CTEXLI is chenodiol for adult CTX. ATEBRIOZ is zilurgisertib, an ALK2 inhibitor approved for FOP from age 12. These are different diseases and mechanisms. LIVMARLI FDA label CTEXLI FDA label ATEBRIOZ FDA label

The development portfolio includes anti-HBsAg antibody brelovitug for HDV, volixibat for cholestatic pruritus, label expansions and PDE4D inhibitor MRM-3379. Q3 results and current guidance · November 3

Brelovitug AZURE-4: positive, with a specific comparison

In 113 randomized patients, combined virologic response and ALT normalization was 59% weekly, 44% monthly and 0% delayed treatment. The open-label study compares active week 24 with delayed-control week 12, after which the delayed group begins drug. It is not a blinded placebo comparison at week 24. AZURE-4 results · November 10 AZURE-4 trial record

These biomarker responses do not establish a cure or long-term elimination of liver complications. Brelovitug remains investigational. AZURE-4 results · November 10

MIRM earnings and cash: growth with transaction complexity

Q3 sales comprise LIVMARLI $133.447M and Bile Acid Medicines $52.274M. Ordinary R&D was $107.931M, acquired IPR&D $13.500M and SG&A $88.864M. Net loss was $40.766M. Q3 2026 Form 10-Q · November 3

Nine-month net loss of $898.148M includes $756.237M acquired IPR&D. September liquidity consists of cash $243.188M, short-term investments $130.499M and long-term investments $126.768M. Management describes funding for current plans for at least twelve months from statement issuance and beyond; no fixed exhaustion date is inferred. Q3 2026 Form 10-Q · November 3

MIRM share dilution and debt

September common shares were 65,209,474 versus 51,896,391 at year-end, an increase of about 25.65%. The October 30 count is 65,282,044. September awards total 10,726,582, alongside pre-funded warrants, holdback shares and convertible claims. Q3 2026 Form 10-Q · November 3

Convertible principal totals $749.035M, comprising $59.035M due 2029 and $690M due 2032. The carrying value is $731.250M. Zero coupon does not remove the 2032 repayment obligation. Q3 2026 Form 10-Q · November 3

Merlintrader Health Score · MIRM

3.60out of 5
Financial position3.5

Cash and investments of $500.455M support a growing commercial base, alongside $749.035M nominal convertible debt and acquisition-affected cash use. Q3 2026 Form 10-Q · November 3

Catalysts4.5

Positive AZURE-4 is already disclosed; VANTAGE is expected Q1 2027 and multiple applications H1 2027. These are company forecasts, as planned applications rather than established FDA review dates. Q3 results and current guidance · November 3 AZURE-4 results · November 10

Dilution2.0

Common shares rose about 25.65% through September; awards, pre-funded warrants and convertibles add potential claims. Q3 2026 Form 10-Q · November 3

Trading liquidity4.0

An established listed security with an active daily price history; trading conditions can change around clinical disclosures.

Execution4.0

Commercial growth, ATEBRIOZ approval and positive late-stage data show progress; submissions and launches still require execution. Q3 results and current guidance · November 3 ATEBRIOZ FDA approval · September 25

Weighted calculation: 3.5 × 30% + 4.5 × 30% + 2.0 × 20% + 4.0 × 10% + 4.0 × 10% = 3.60 out of 5. Editorial assessment as of November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of clinical success.

MIRM red flags

MIRM Stock FAQ: Mirum Pharmaceuticals Questions Answered

When is the next MIRM stock catalyst?

As of November 12, 2026, Mirum expects volixibat VANTAGE topline data in PBC in Q1 2027. It plans the volixibat PSC NDA, brelovitug BLA and LIVMARLI and ATEBRIOZ supplemental applications in H1 2027. These are company forecast windows. Q3 results and current guidance · November 3 AZURE-4 results · November 10

Are Mirum Pharmaceuticals medicines FDA approved?

As of November 12, 2026, Mirum markets LIVMARLI, CHOLBAM, CTEXLI and ATEBRIOZ. ATEBRIOZ was approved September 25 for FOP from age twelve; younger-pediatric use remains investigational. Brelovitug and volixibat remain development programs. Q3 2026 Form 10-Q · November 3 ATEBRIOZ FDA label Q3 results and current guidance · November 3

How much cash does Mirum Pharmaceuticals have?

At September 30, 2026, Mirum had $500.455M in cash, cash equivalents and investments, excluding $1.735M restricted cash. Management described funding for current plans for at least twelve months from statement issuance and beyond. Nominal convertible debt was $749.035M. Q3 2026 Form 10-Q · November 3

Is MIRM stock exposed to share dilution?

At September 30, 2026, Mirum had 65,209,474 common shares, up from 51,896,391 at year-end. Options, RSUs and PSUs totaled 10,726,582, with further pre-funded, holdback and convertible claims. The October 30 common count was 65,282,044. Q3 2026 Form 10-Q · November 3

When did Mirum Pharmaceuticals report Q3 2026 earnings?

Mirum reported Q3 2026 results on November 3, 2026. Net product sales were $185.721M and net loss $40.766M for the quarter ended September 30. The company raised full-year net product-sales guidance to $715–720M. Q3 results and current guidance · November 3 Q3 2026 Form 10-Q · November 3

What does Mirum Pharmaceuticals do?

As of November 12, 2026, Mirum is a rare-disease company with commercial medicines for selected liver disorders and FOP. Its development portfolio includes brelovitug for hepatitis delta, volixibat for cholestatic pruritus and MRM-3379 for fragile X syndrome. Q3 results and current guidance · November 3

Did Mirum Pharmaceuticals AZURE-4 meet its endpoint?

On November 10, 2026, Mirum announced positive AZURE-4 results. Combined virologic response and ALT normalization was 59% weekly, 44% monthly and 0% delayed treatment. The open-label design compares active week 24 with delayed-control week 12. AZURE-4 results · November 10 AZURE-4 trial record

How much convertible debt does Mirum Pharmaceuticals have?

At September 30, 2026, Mirum had $749.035M nominal convertible principal, with $731.250M net carrying value. The notes comprise $59.035M due 2029 and $690M due 2032; the latter have a zero coupon but retain repayment and potential conversion obligations. Q3 2026 Form 10-Q · November 3

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $MIRM or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.